Analgesic, anti-inflammatory, antipyretic and toxicological evaluation of some newer 3-methyl pyrazolone derivatives

Saudi Pharmaceutical Journal

Volumn 19, Issue 2, 2011, Pages 115-122

  Mariappan, G ^a   Saha, B P ^a   Sutharson, L ^a   Singh, Ankit ^a   Garg, S ^a   Pandey, L ^a   Kumar, Deepak ^a  

^a HIMALAYAN PHARMACY INSTITUTE   (India)

Author keywords

Acute and subacute toxicity; Blood dyscrasias; Non steroidal anti inflammatory; Pyrazolone

Indexed keywords

4 [2 CHLOROBENZYLIDINE] 3 METHYLPYRAZOLIN 5(4H) ONE; 4 [4 N DIMETHYLAMINO BENZYLIDINE] 3 METHYL PYRAZOLIN 5(4H) ONE; 4 [BENZYLIDINE] 3 METHYLPYRAZOLIN 5(4H) ONE; ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; HEMOGLOBIN; INDOMETACIN; PARACETAMOL; PENTAZOCINE; PYRAZOLONE DERIVATIVE; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIPYRETIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHEMICAL ANALYSIS; CONTROLLED STUDY; ERYTHROCYTE; FEMALE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; LEUKOCYTE COUNT; MALE; NONHUMAN; RAT; TOXICOLOGY;

EID: 79952708154     PISSN: 13190164     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsps.2011.01.003     Document Type: Article

References (44)

1. Adam S.E.I. Toxic effects of Francoeuria crispa in rats. Phytother. Res. 1998, 2:476-479.
2. Anderson A.J., Bocklehurst W.E., Wills A.L. Evidence for the role of lysosomes in the formation of prostaglandin during carrageenan-induced inflammation in rat. Pharmacol. Res. Commun. 1971, 3:13-17.
3. Armour D.F.E., Blood F.R., Belden D.A. In the Manual of Laboratory Work in Mammalian Physiology 1965, The University of Chicago Press, Liilious, Chicago, pp. 4-6. third ed.
4. Badaweya, El-Sayed A.M., El-Ashmawey, Ibrahim M. Nonsteroidal anti-inflammatory agents - Part 1: Anti-inflammatory, analgesic and antipyretic activity of some new 1-(pyrimidin-2-yl)-3-pyrazolin-5-ones and 2-(pyrimidin-2-yl)-1,2,4,5,6,7-hexahydro-3H indazol-3-ones. J. Med. Chem. 1998, 33:349-361.
5. Bentur Y., Cohen O. Dipyrone overdose. J. Toxicol. Clin. Toxicol. 2004, 42:261-265.
6. Brito A.R.M.S., Antonio M.A. Oral antiinflammatory and antiulcerogenic activities of a hydroalcoholic extract and partitioned fractions of Turnera ulmifolia (Turneraceae). J. Ethnopharmacol. 1998, 61:215-228.
7. Brogden R.N. Pyrazolone derivatives. Drugs 1986, 32(4):60-70.
8. Chou C.T. The anti-inflammatory effect of Tripterygium wilfordii on adjuvant-induced paw edema in rats and inflammatory mediators release. Phytother. Res. 1997, 11:152-154.
9. Crook M.A. Clinical Chemistry and Metabolic Medicine 2006, Hodder Arnold, London, p. 426. seventh ed.
10. D'Armour F.E., Smith D.L. A method for determining loss of pain sensation. J. Pharmacol. Exp. Ther. 1941, 72:74-79.
11. Das N., Verma A., Shrivastava P.K., Shrivastava S.K. Synthesis and biological evaluation of some new aryl pyrazol-3-one derivatives as potential hypoglycemic agents. Indian J. Chem. 2008, 47B:1555-1558.
12. Derelanko M.J., Hollinger M.A. Acute, subacute and chronic toxicology. Hand Book of Toxicology 2002, CRC Press, New York, pp. 69-127. second ed.
13. Dirosa M., Giroud J.P., Willoughby D.A. Studies of the acute inflammatory response induced in rats in different sites by carrageenan and turpentine. J. Pathol. 1971, 104:15-29.
14. Dixon W.J. Staircase bioassay: the Up and Down method. Neurosci. Biobehav. Rev. 1999, 15:47-50.
15. Dray A. Inflammatory mediators of pain. Br. J. Anaesth. 1995, 75:125-131.
16. Flower R.J. Management of rheumatoid arthritis and osteoarthritis. Am. J. Med. 1983, 75(4):1-91.
17. Flower R.J., Vane J.R. Inhibition of prostaglandins synthesis. Biochem. Pharmacol. 1974, 23:1439-1450.
18. Foegh M.L., Ramwell P.W. The eicosanoids: prostaglandins, thromboxanes, leukotrienes, and related compounds. Basic and Clinical Pharmacology 2001, 311-325. Lange Medical Books/McGraw-Hill, New York. eighth ed. B.G. Kartzung (Ed.).
19. Furst D.E., Munster T. Nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, nonopoid analgesics and drugs used in gout. Basic and Clinical Pharmacology 2001, 596-623. Lange Medical Books/McGraw-Hill, New York. eighth ed. B.G. Kartzung (Ed.).
20. Ghai C.L. Textbook of Practical Physiology 1990, Jaypee Medical Publishers, New Delhi, pp. 102-104.
21. Ghosh M.N. Fundamentals of Experimental Pharmacology 1970, Hilton and Company, Kolkata, pp. 176-183. fourth ed.
22. Graham G.G., Scott K.F. Mechanisms of action of paracetamol and related analgesics. Inflammopharmacology 2003, 11:401-413.
23. Hoffman R., Benz E.J., Shattil S.J. Hematology: Basic Principles and Practice 2005, Churchill Livingstone, Philadelphia, p. 2674. fourth ed.
24. Jannoff A., Zweifach B.W. Production of inflammatory changes in the micro-circulation by cationic proteins extracted from lysosomes. J. Exp. Med. 1964, 120:747-764.
25. Koster R., Anderson M., De Beer E.J. Acetic acid for analgesic screening. Fed. Proc. 1959, 18:412-416.
26. Kytridis V.P., Manetas Y. Mesophyll versus epidermal anthocyanins as potential in vivo antioxidants: evidence linking the putative antioxidant role to the proximity of oxy-radical source. J. Exp. Bot. 2006, 57:2203-2210.
27. Lu W.L., Zhang Q., Zheng L., Wang H., Li R.Y., Zhang L.F. Antipyretic, analgesic and anti-inflammatory activities of ketoprofen beta-cyclodextrin inclusion complexes in animals. Biol. Pharm. Bull. 2004, 27(10):1516-1520.
28. Mariappan G., Saha B.P., Sutharson L., Haldar A. Synthesis and bioactivtiy evaluation of pyrazolone derivatives. Indian J.Chem. 2010, 47B:1671-1674.
29. McKnight D.C., Mills R.G., Bray J.J., Crag P.A. Human Physiology 1999, Churchill Livingstone, pp. 290-294. fourth ed.
30. Mcpherson R.A., Pincus M.R. Henry's Clinical Diagnosis and Management by Laboratory Methods 2007, WB Saunders, Philadelphia, pp. 459-460. 21st ed.
31. Murugesh N., Vember S., Damondaran C. Studies on erythrocyte membrane IV: in vitro haemolytic activity of oleander extract. Toxicol. Lett. 1981, 8:33-38.
32. Newbould B.B. Chemotherapy of arthritis induced in rats by mycobacterial adjuvant. Br. J. Pharmacol. 1963, 21:127-136.
33. Roberts J.L., Morrow J.D. Analgesic-antipyretic and anti-inflammatory agents and drugs employed in the treatment of gout. Goodman and Gilman's The Pharmacological Basis of Therapeutics 2001, 687-731. McGraw Hill Co., New York. 10th ed. A.G. Gilman, J.G. Hardman, L.E. Limbird (Eds.).
34. Robins S.L. Lymph Nodes and Spleen: Pathologic Basis of Disease 1974, WB Saunders Co., Philadelphia, p. 1050.
35. Sahu S.K., Azam A.M., Banerjee M., Choudhary P., Sutradhar S., Panda P.K., Misra P.K. Synthesis and biological evaluation of 3-(pthalimidomethyl)-4-(5-substituted isoxazoline and pyrazoline) substituted benzanilides. J. Indian Chem. Soc. 2007, 84:1011-1015.
36. Saraf M.N., Ghooi R.B., Patavardhan B.K. Studies on the mechanism of action of Semecarpus anacardum in rheumatoid arthritis. J. Ethnopharmacol. 1989, 25:159-164.
37. Sil D., Kumar R., Sharon A., Maulik, Prakas R., Ram V. Stereoselective alkenylation of 1,3-disubstituted pyrazol-5-one through ring transformation of 2H-pyran-2-ones. Tetrahedron Lett. 2005, 46(22):3807-3809.
38. Singh D., Singh D. Synthesis and antifungal activity of some 4-arylmetylene derivatives of substituted pyrazolones. J. Indian Chem. Soc. 1991, 68:165-167.
39. Uetrecht J.P., Ma H.M., MacKnight E., McClelland R. Oxidation of aminopyrine by hypochlorite to a reactive dication: possible implications for aminopyrine-induced agranulocytosis. Chem. Res. Toxicol. 1995, 8:226-233.
40. Vane J.R., Bolting R.M. New insights into the mode of action of anti-inflammatory drugs. Inflamm. Res. 1995, 44(1):1-10.
41. Winter C.A., Risely E.A., Nuss G.W. Carrageenan induced edema in hind paw of the rat as an assay for anti-inflammatory drug. Proc. Soc. Exp. Biol. Med. 1962, 111:544-547.
42. Wintrobe M.M., Lee G.R., Boggs D.R., Bithel T.C., Athens J.W., Foeresters J. Clinical Hematology 1976, Les and Febiger, Philadelphia, p. 961. seventh ed.
43. Yu E.T. Milestone in the treatment of gout. Am. J. Med. 1974, 56(4):676-683.
44. Yukihito H., Daisuke J., Kazuaki C., Masao Y. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a novel free radical scavenger, for treatment of cardiovascular diseases. Recent Patent Cardiovasc. Drug Discov. 2006, 1:85-93.